Jädersten at al.6 compared 121 Nordic patients with MDS treated with erythropoietin plus granulocyte colony-stimulating factor (G-CSF) to a disease and time-matched cohort of 237 patients from Pavia, Italy, who received no therapy. The gene discussed is EPO; the disease is myelodysplastic syndrome.